318 related articles for article (PubMed ID: 19569180)
41. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
[TBL] [Abstract][Full Text] [Related]
43. Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Govindan SV; Kulsum S; Pandian RS; Das D; Seshadri M; Hicks W; Kuriakose MA; Suresh A
Mol Med Rep; 2015 Aug; 12(2):3025-32. PubMed ID: 25962396
[TBL] [Abstract][Full Text] [Related]
44. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
45. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.
Li F; Shanmugam MK; Siveen KS; Wang F; Ong TH; Loo SY; Swamy MM; Mandal S; Kumar AP; Goh BC; Kundu T; Ahn KS; Wang LZ; Hui KM; Sethi G
Oncotarget; 2015 Mar; 6(7):5147-63. PubMed ID: 25762616
[TBL] [Abstract][Full Text] [Related]
46. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of midkine induces cisplatin resistance in human oral squamous cell carcinoma.
Ota T; Jono H; Ota K; Shinriki S; Ueda M; Sueyoshi T; Nakatani K; Hiraishi Y; Wada T; Fujita S; Obayashi K; Shinohara M; Ando Y
Oncol Rep; 2012 May; 27(5):1674-80. PubMed ID: 22344722
[TBL] [Abstract][Full Text] [Related]
48. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
[TBL] [Abstract][Full Text] [Related]
49. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
[TBL] [Abstract][Full Text] [Related]
50. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
51. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
52. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
[TBL] [Abstract][Full Text] [Related]
53. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines.
Yu ZW; Zhong LP; Ji T; Zhang P; Chen WT; Zhang CP
Oral Oncol; 2010 Apr; 46(4):317-22. PubMed ID: 20219416
[TBL] [Abstract][Full Text] [Related]
54. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
[TBL] [Abstract][Full Text] [Related]
55. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
56. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
57. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
[TBL] [Abstract][Full Text] [Related]
58. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
[TBL] [Abstract][Full Text] [Related]
59. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.
Lee J; Jiffar T; Kupferman ME
PLoS One; 2012; 7(1):e30246. PubMed ID: 22276165
[TBL] [Abstract][Full Text] [Related]
60. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]